Tilray Brands snaps six straight sessions of losses

Tilray Brands (NASDAQ:TLRY) shares snapped six straight sessions of losses, as the stock rose 1.9% higher at $1.32 on Thursday.

The cannabis stock lost over 10% in the preceding six sessions. The stock has lost about 43% so far this year, compared to the near 25% rise in the broader S&P 500 Index.

TLRY is down 21% over the past one month.

Looking at Seeking Alpha’s Quant Rating, TLRY has a Hold rating with a score of 2.6 out of 5. The company received B in the prospect of profitability, D+ in momentum, while it got a A- growth factor.

Turning to the Wall Street community, four analysts gave DOW a Buy and above. Nine analysts have given the stock a Hold recommendation, and no one recommended Sell or lower.

Seeking Alpha analysts are also cautious and see the stock as a Hold.

Earlier in November, TLRY reported positive results from a study of an oral cannabis extract in the treatment of chemotherapy-induced nausea and vomiting in patients who have not adequately responded to standard anti-nausea medications.

“Tilray has done a horrible job of M&A in the cannabis industry, and it has failed to meet its own expectations on revenue, adjusted EBITDA or market share. The Canadian cannabis market has matured, and there are better operators there,” pointed out a recent Seeking Alpha analysis.